Article Versions Notes

Cheng X, Hübner R, von Kiedrowski V, Fricker G, Schirrmacher R, Wängler C, Wängler B. Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α_vβ₃ and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas? Pharmaceuticals. 2021; 14(6):547. https://doi.org/10.3390/ph14060547

Cheng, Xia, Ralph Hübner, Valeska von Kiedrowski, Gert Fricker, Ralf Schirrmacher, Carmen Wängler, and Björn Wängler. 2021. "Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α_vβ₃ and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?" Pharmaceuticals 14, no. 6: 547. https://doi.org/10.3390/ph14060547

Cheng, X., Hübner, R., von Kiedrowski, V., Fricker, G., Schirrmacher, R., Wängler, C., & Wängler, B. (2021). Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin α_vβ₃ and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas? Pharmaceuticals, 14(6), 547. https://doi.org/10.3390/ph14060547